Recovery from addiction is a challenging journey, filled with both triumphs and setbacks. For individuals seeking long-term sobriety, relapse can be a disheartening reality. However, recent findings ...
The FDA has approved a supplemental new drug application for lumateperone (Caplyta, Johnson & Johnson) for the prevention of relapse in adults with schizophrenia. The label expansion was based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results